Last year 700,000 people died from bacterial infection yC hatchery company Felix based on the virus research new treatment

According to statistics released by the United Nations, more than 700,000 people worldwide died of bacterial infections in 2019, including more than 35,000 Americans. If we do nothing, that number could top 10 million by 2050. One of the main causes of bacterial infections is the overuse of antibiotics in medical institutions and farming farms.

Last year 700,000 people died from bacterial infection yC hatchery company Felix based on the virus research new treatment

Over the past few years, we’ve tried a lot of drugs to kill all harmful bacteria, but these have not worked very well to kill most, but not all, of harmful bacteria. Felix, the new ester startup in the Y Combinator incubator, hopes to use a novel technology to use viruses to stop bacterial infections.

Given the new coronavirus, which is currently raging around the world, it is often bad in the eyes of ordinary people and even death. But Felix’s co-founder, Robert McBride, explains that Felix’s core technology allows the virus to attack specific parts of the bacteria. This not only kills harmful bacteria, but also prevents it from evolving and becoming resistant again.

Last year 700,000 people died from bacterial infection yC hatchery company Felix based on the virus research new treatment

In fact, there is no precedent for the use of viruses against bacteria, as early as 1915 British researchers discovered phages, in 1940 the United States Eli Lilly and Company. Right began commercial phage therapy. By then, however, antibiotics had emerged, and Western scientists had not explored the therapy further.

Last year 700,000 people died from bacterial infection yC hatchery company Felix based on the virus research new treatment

“Compared to conventional antibiotics, we can develop therapies in less time and at less cost, because our goal is orphan indications, and we already know that our treatments can work in the human body,” McBride told TechCrunch. We believe that methods that re-sensitivity bacteria to traditional antibiotics may be widely used clinically.”